TMC Life Sciences Berhad
TMC Life Sciences Berhad, a prominent player in the biotechnology and healthcare sector, is headquartered in Malaysia. Founded in 1994, the company has established itself as a leader in providing innovative healthcare solutions, particularly in the fields of regenerative medicine and clinical research. With a strong operational presence across Southeast Asia, TMC Life Sciences focuses on advanced medical technologies and services that enhance patient care. The company offers a range of core products and services, including stem cell therapies and clinical trial management, distinguished by their commitment to quality and scientific excellence. TMC Life Sciences has achieved significant milestones, positioning itself as a trusted name in the industry, recognised for its contributions to medical advancements and patient outcomes.
DitchCarbon Score
How does TMC Life Sciences Berhad's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
TMC Life Sciences Berhad's score of 19 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
TMC Life Sciences Berhad's reported carbon emissions
In 2023, TMC Life Sciences Berhad reported total carbon emissions of approximately 39,000,410 kg CO2e, comprising 600,410 kg CO2e from Scope 1, 36,081,000 kg CO2e from Scope 2, and 1,814,000 kg CO2e from Scope 3, specifically related to business travel. This data reflects a comprehensive approach to emissions reporting, with disclosures for all three scopes. Comparatively, in 2022, the company recorded emissions of about 31,190,000 kg CO2e from Scope 2 and 316,050 kg CO2e from Scope 1, indicating a significant increase in emissions in 2023. The emissions from Scope 3 were not reported in 2022, highlighting a growing awareness and tracking of indirect emissions. TMC Life Sciences Berhad has not set specific reduction targets or climate pledges, nor does it appear to have cascaded any Science-Based Targets Initiative (SBTi) commitments from its parent company, Thomson Medical Group Limited. The absence of documented reduction initiatives suggests a need for further development in their climate strategy. The company’s emissions data is inherited from its corporate family, with the performance data sourced directly from TMC Life Sciences Berhad. As a current subsidiary of Thomson Medical Group Limited, TMC Life Sciences is positioned within a broader context of healthcare and life sciences, where emissions management is increasingly critical.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 263,150 | 000,000 | 000,000 |
| Scope 2 | 14,390,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
TMC Life Sciences Berhad is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
